<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Reinventing a National Manufacturing Strategy</title>
	<atom:link href="http://blog.pharmtech.com/2011/08/09/reinventing-a-national-manufacturing-strategy/feed/" rel="self" type="application/rss+xml" />
	<link>http://blog.pharmtech.com/2011/08/09/reinventing-a-national-manufacturing-strategy/</link>
	<description>The blog of Pharmaceutical Technology magazine</description>
	<lastBuildDate>Thu, 09 May 2013 23:30:55 -0400</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: cliffintokyo</title>
		<link>http://blog.pharmtech.com/2011/08/09/reinventing-a-national-manufacturing-strategy/comment-page-1/#comment-39738</link>
		<dc:creator>cliffintokyo</dc:creator>
		<pubDate>Mon, 15 Aug 2011 08:57:59 +0000</pubDate>
		<guid isPermaLink="false">http://blog.pharmtech.com/?p=4508#comment-39738</guid>
		<description>A &#039;national manufacturing strategy&#039;, even just for pharma, may be a little too &#039;socialist&#039; a concept for many US pundits.
US gov/FDA probably does need to bring US pharma together to seriously consider the risks of not having a manufacturing base of excellence in quality within the US for producing complex NCE APIs, biotech APIs, and specialist Drug Products, perhaps solely (or mainly) for the US market. 
Overseas factories operated by US pharma should probably produce products for overseas markets, with regulatory enforcement by local authorities, according to their own standards.</description>
		<content:encoded><![CDATA[<p>A &#8216;national manufacturing strategy&#8217;, even just for pharma, may be a little too &#8217;socialist&#8217; a concept for many US pundits.<br />
US gov/FDA probably does need to bring US pharma together to seriously consider the risks of not having a manufacturing base of excellence in quality within the US for producing complex NCE APIs, biotech APIs, and specialist Drug Products, perhaps solely (or mainly) for the US market.<br />
Overseas factories operated by US pharma should probably produce products for overseas markets, with regulatory enforcement by local authorities, according to their own standards.</p>
]]></content:encoded>
	</item>
</channel>
</rss>
